Clinical Trials
32 trialsRadiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
PHERGAIN-2
MedSIR
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
DTP
The Methodist Hospital Research Institute
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
BRIDGET
Duke University
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
PETREMAC
Haukeland University Hospital
PATINA
Alliance Foundation Trials, LLC.
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
PANSY
Fudan University
MARGOT
Dana-Farber Cancer Institute
InTTercePT
UNICANCER
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
City of Hope Medical Center
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Dana-Farber Cancer Institute
Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
Icahn School of Medicine at Mount Sinai
Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
University of California, Irvine
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
University of Texas Southwestern Medical Center
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
City of Hope Medical Center
SPORTNATHy
The Greater Poland Cancer Centre
PHERGain
MedSIR
BOLD-1
Helsinki University Central Hospital
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Detect V / CHEVENDO (Chemo vs. Endo)
University of Ulm
TRAIN-2
The Netherlands Cancer Institute
APTneo
Fondazione Michelangelo
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
Sun Yat-sen University
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Shanghai Jiao Tong University School of Medicine
PREDIX HER2
Karolinska University Hospital